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Alzheimer’s disease (AD) is an age-related disorder that causes a loss of 
brain function. Hyperphosphorylation of tau and the subsequent formation of 
intracellular neurofibrillary tangles (NFTs) are implicated in the pathogenesis 
of AD. Hyperphosphorylated tau accumulates into insoluble paired helical 
filaments that aggregate into NFTs; therefore, regulation of tau 
phosphorylation represents an important treatment approach for AD. Heat 
shock protein 27 (Hsp27) plays a specific role in human neurodegenerative 
diseases; however, few studies have examined its therapeutic effect. In this 
study, we induced tau hyperphosphorylation using okadaic acid, which is a 
protein phosphatase inhibitor, and generated a fusion protein of Hsp27 and 
the protein transduction domain of the HIV Tat protein (Tat-Hsp27) to 
enhance the delivery of Hsp27. Tat-Hsp27 was delivered into SH-SY5Y 
neuroblastoma cells following a 2 h treatment, and the transduction level was 
proportional to the Tat-Hsp27 concentration. Additionally, Tat-Hsp27 
reduced the level of hyperphosphorylated tau and protected cells from 
apoptotic cell death caused by abnormal tau adjajggregates. These results 
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1. Introduction  
 
Alzheimer’s disease (AD) is a progressive neurological disorder that 
causes memory loss. Various pathological hallmarks of AD include 
synaptic and neuronal loss, amyloid plaques primarily composed of the 
42-residue hydrophobic β-amyloid peptide (Aβ) [1] and neurofibrillary 
tangles (NFTs) composed of aggregates of hyperphosphorylated tau, 
which is a microtubule-associated protein [2]. Amyloid plaques and 
NFTs are considered the primary factors involved in the pathogenesis 
of AD [3]. Although previous studies have primarily focused on the 
role of β-amyloid peptides, recent studies on the role of tau in AD 
pathogenesis have indicated that hyperphosphorylated tau aggregates 
into insoluble paired helical filaments (PHFs), which induce neuronal 
dysfunction [4]. Moreover, these two pathological hallmarks 
demonstrate synergistic effects on synaptic dysfunction [5, 6].  
As a microtubule-associated protein, aggregates of normal tau protect 
cells against toxic hyperphosphorylation, although neuronal death 
occurred following a period of survival [7]. However, tau is not only 
abnormally phosphorylated but also aggregates into insoluble forms 
such as PHFs and NFTs [8, 9] in various AD mouse models [10-12]. 
Therefore, an approach that reduces the level of hyperphosphorylated  
 
- 2 - 
 
tau would represent a valuable treatment for AD [13]. Tau can bind heat 
shock proteins (HSPs), which trigger the recruitment of CHIP (which is 
a co-chaperone that exhibits E3 activity), to the complex. CHIP induces 
the ubiquitination of tau and activates its degradation when tau is 
defective [14]. Hsp27 directly associates with hyperphosphorylated tau 
or PHFs and regulates cell survival by eliminating tau aggregates [15].  
Heat shock proteins are induced in response to cellular stress as 
molecular chaperones that inhibit protein aggregation [16]. HSPs can 
prevent apoptosis and increase cell viability during cellular stress [17, 
18]. HSPs are also critical regulators of normal neural physiological 
function and cell stress responses [19-21]. However, the therapeutic 
effects of exogenous Hsp27 on disease models have not been 
investigated. Therefore we sought to determine whether Hsp27 can 
reduce hyperphosphorylated tau in AD-induced SH-SY5Y cells.  
To more effectively deliver Hsp27 into cells, we combined the HIV 
protein transduction domain (PTD) Tat with the Hsp27 protein (Tat-
Hsp27). HIV Tat (11 residues, YGRKKRRQRRR), can rapidly 
transduce into cells [22] and deliver full-length proteins into cells [23]. 
As expected, Tat-Hsp27 effectively reduced the phosphorylation of tau 
and rescued the cell death caused by abnormal tau aggregates. 
Therefore, our study suggests that Tat-Hsp27 may represent a potential 
protein therapeutic for tau-induced neurodegeneration.  
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2. Materials and Methods 
Construction of the expression vector 
We designed a bacterial expression vector (His6-Tat-Hsp27) 
containing hexahistidine leader sequence, 11-amino acid Tat PTD 
sequence (YGRKKRRQRRR), and Hsp27 protein sequence. The 
Hsp27 fragment (BD Bioscience) was generated by PCR using human 
cDNA as a template and oligonucleotide primers containing BamHI 
and XhoI restriction sites. The pET-28a vector (Novagen) and the Tat 
PTD were digested with NdeI and BamHI and ligated. The ligated 
vector was transformed into chemically competent DH5α E. coli cells 
(Enzynomics, Korea). After purification of the plasmid containing the 
Tat PTD, the plasmid and the Hsp27 fragment were digested with 
BamHI and XhoI and ligated. The recombinant plasmid (pET21a-Tat-
Hsp27) was transformed into competent DH5α E. coli cells for plasmid 
purification. 
Expression and purification of Hsp27 
The recombinant plasmid (His6-Tat-Hsp27) was transformed into the 
E. coli strain BL21(DE3) for protein expression. Transformed cells 
were plated on an LB agar (Merck) plate containing kanamycin 
(Sigma-Aldrich) and incubated overnight at 37°C. Two hundred  
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milliliters of LB medium containing 1 mM kanamycin was inoculated 
with a single colony and incubated overnight at 37°C with shaking at 
200 rpm. The following day, 1 L of LB medium was inoculated with 
this preculture and incubated at 37°C until an OD600 of 0.5. Protein 
expression was induced by the addition of Isopropyl β-D-1-
thiogalactopyranoside (MB cell, Korea) at a final concentration of 1 
mM, and the cells were incubated at 37°C for an additional 4 h. The 
cells were centrifuged at 6,000 rpm for 15 min at 4°C and resuspended 
in binding buffer (20 mM Tris-HCl, 500 mM NaCl, 35 mM imidazole, 
pH 7.5). Cells were lysed by sonication on ice using a sonicator (Sonics 
Vibra-Cell VCX 750, Sonic & Materials Inc., USA) with 1-s pulses and 
8-s pauses for 30 min. After sonication, the lysates were centrifuged at 
10,000 rpm for 15 min. The clarified lysate was loaded onto a pre-
equilibrated HisTrap HP column (GE Healthcare). His-tagged Tat-
Hsp27 protein was eluted with elution buffer (20 mM Tris-HCl, 500 
mM NaCl, 1 M imidazole, pH 7.5). His-tagged Tat-Hsp27 was further 
purified using size exclusion chromatography on a HiLoad 16/600 
Superdex 200 prep grade column (GE Healthcare) using 20 mM Tris-
HCl (pH 7.5) and 100 mM NaCl. For the detection of Tat-Hsp27 
delivery into cells, we conjugated FITC to Tat-Hsp27 using an FITC 
labeling kit (Thermo Scientific). The concentration of protein was 
determined using BCA protein assay kit (Pierce). 
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Cell culture 
SH-SY5Y human neuroblastoma cells were grown in Roswell Park 
Memorial Institute 1640 medium supplemented with 10% fetal bovine 
serum and 1% antibiotic-antimycotic under an atmosphere of 5% CO2 
and 95% air (all from WELGENE). The medium was refreshed every 
three days. Cells below passage 24 were used for experiments. 
 
Western blot analysis 
For Western blot analysis, the cells treated with Tat-Hsp27 and 
okadaic acid were washed in DPBS and harvested in RIPA buffer 
(Pierce). To prevent from further phosphorylation, we added Protease 
inhibitor cocktail and phosphatase inhibitor cocktail (both from Sigma-
Aldrich) into the cell lysates. Lysates were then centrifuged at 15,000 x 
g for 15 min at 4°C. The supernatant was separated in a 12% SDS-
PAGE gel, and the proteins were transferred to a nitrocellulose 
membrane. After blocking in 5% skim milk/TBST (Tris-buffered saline 
and 0.1% Tween 20, pH 7.5), the membrane was washed in TBST three 
times (15 min each) and incubated with primary antibody overnight at 
4°C. The membrane was subsequently washed and incubated with the 
appropriate secondary antibody (HRP conjugated goat-anti mouse and  
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goat-anti rabbit) for 2 h at room temperature. Peroxidase-linked anti-
rabbit and anti-mouse IgG were purchased from Santa Cruz 
Biotechnology (USA). Rabbit polyclonal anti-tau phosphoserine 
199/202 antibody and mouse monoclonal anti-tau-1 antibody were 
obtained from Millipore (USA). Anti-human tau monoclonal antibody 




The SH-SY5Y cells were seeded on 2-well slides (Lab-Tek chamber, 
Nalge Nunc, NY) at a density of 5.0 × 10
5
 per well, treated with 2 μM 
Tat-Hsp27 for 2 h, and then treated with 10 nM okadaic acid for 14 h. 
The cells were rinsed two times with PBS and fixed with 4% 
paraformaldehyde for 30 min. The cells were subsequently 
permeabilized for 10 min with 0.5% Triton X-100 followed by three 5-
min washes in PBS. To reduce nonspecific binding, we used PBS 
containing 0.5% bovine serum albumin as blocking buffer. After 
incubation with the blocking buffer for 1 h, the cells were incubated 
with the primary antibody AT8 (anti-phosphorylated-tau antibody) for 
4 h, followed by three 5-min washes. The cells were subsequently 
incubated with goat anti-rabbit (H+L) FITC-conjugated antibody. After 
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washing with PBS, cells were imaged using an image restoration 
microscope (Applied Precision, USA). 
 
Cell viability/cytotoxicity assay 
A cytotoxicity assay was performed using a Cell Counting Kit-8 
(Dojindo, Korea). SH-SY5Y cells were plated in a 96-well plate at 5.0 
× 10
4
 in 100 μL of RPMI 1640 medium containing 10% FBS. After 
incubation for 48 h, cells were treated with 0.5 μM or 2 μM Tat-Hsp27 
for 2 h. Subsequently, various concentrations of okadaic acid were 
added for 8 h to induce abnormally phosphorylated tau. Ten microliters 
of CCK-8 solution was added, and the cells were incubated at 37°C for 
2 h. The absorbance at 450 nm was measured using a microplate reader 
(Molecular Devices Co., Menlo Park, CA). 
 
In situ terminal deoxynucleotidyl transferase dUTP nick-end 
labeling (TUNEL) assay 
SH-SY5Y cells were seeded on a 2-well slide at a density of 5.0 × 10
5
 
per well, treated with 2 μM Tat-Hsp27 for 2 h, and then treated with 10 
nM okadaic acid for 14 h. The cells were fixed by immersion in PBS 
containing 4% formaldehyde (pH 7.4). After washing with PBS, the 
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cells were permeabilized in 0.2% Triton X-100 and washed again. 
After treatment with equilibration buffer, the cells were added to rTdT 
incubation buffer containing nucleotide mix. To terminate the reaction, 
saline-sodium citrate buffer was added to the cells; nuclei were stained 
with VECTASHIELD + DAPI. The cells were analyzed under a 
fluorescence microscope at 520 nm (green fluorescence) and 460 nm 
(blue, DAPI).  
 
Statistical analysis 
The data are expressed as the mean ± SE and were calculated using an 
unpaired Student’s t-test. A value of p < 0.05 indicates a significant 
difference. 
 
3. Results  
The sequence encoding Tat-Hsp27 fusion protein was cloned into the 
pET28a vector, which produces a recombinant protein with a 
hexahistidine tag (Fig.1A) and purified using affinity purification and 
size exclusion chromatography. Fractions containing His-tagged Tat-
Hsp27 were identified using 12% SDS-PAGE analysis with Coomassie 
Brilliant Blue staining. His-tagged Tat-Hsp27 in fractions 1-6 exhibited 
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high affinity for the affinity matrix. The eluted His-tagged Tat-Hsp27 
was further purified using size exclusion chromatography. Fractions 
containing His-tagged Tat-Hsp27 were identified using 12% SDS-
PAGE with Coomassie Brilliant Blue staining. His-tagged Tat-Hsp27 
eluted as a single peak from size exclusion chromatography, as 
confirmed by Western blot analysis (Fig. 1D), and migrated to a 
position slightly above the 25-kDa molecular weight marker in 12% 
SDS-PAGE analysis. The purified recombinant His-tagged Tat-Hsp27 
was concentrated to 1.438 mg/mL as determined using the BCA assay. 
To investigate whether Tat-Hsp27 could be effectively delivered into 
cells, we conjugated FITC to Tat-Hsp27. Image restoration microscopy 
indicated that FITC-Tat-Hsp27 was efficiently delivered into SH-SY5Y 
cells following treatment for 2 h at a concentration of 2 μM, in contrast 
to 2 μM wt-Hsp27. We also performed Western blot analysis to 
confirm the intracellular delivery of Tat-Hsp27 and to determine 
whether its transduction is dependent on the Tat-Hsp27 concentration. 
SH-SY5Y cells were treated with Tat-Hsp27 for 2 h and were lysed 
using RIPA buffer. As shown in Figure 2B, Hsp27 was present in the 
lysate of SH-SY5Y cells treated with 2 and 5 μM Tat-Hsp27, whereas 
equivalent concentrations of wt-Hsp27 did not transduce cells. 
Additionally, increasing the concentration of Tat-Hsp27 used to treat 
cells resulted in an increased level of delivered protein. Therefore, the 
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recombinant Tat-Hsp27 can be delivered into cells in a concentration-
dependent manner. 
 Because Hsp27 is known to have an effect on phosphorylation, we 
investigated whether Hsp27 can reduce the level of 
hyperphosphorylated tau, which is implicated in the pathogenesis of 
AD. SH-SY5Y cells were treated with 2 or 5 μM Tat-Hsp27 for 2 h, 
and the phosphorylation of normal tau was induced by the addition of 
50 or 100 nM okadaic acid. To quantify the relative phosphorylation, 
we normalized the level of phosphorylated tau (p-tau) in Western blot 
analysis to the level of β-actin using SigmaPlot software. Following 
treatment with 50 or 100 nM okadaic acid for 2 h, the level of 
phosphorylated tau was approximately 1.5-fold or 2-fold greater than 
the control group, respectively. Following treatment with 50 nM 
okadaic acid, the level of p-tau in cells pretreated with 2 μM and 5 μM 
Tat-Hsp27 decreased with an increasing concentration of Tat-Hsp27 
(Fig. 3). In contrast, following treatment with 100 nM okadaic acid, 
cells pretreated with 5 μM Tat-Hsp27 contained slightly higher levels 
of p-tau than cells pretreated with 2 μM Tat-Hsp27. This finding 
suggest that when tau is hyperphosphorylated, a high concentration of 
Tat-Hsp27 has a negative effect on the reduction in 
hyperphosphorylated tau. Therefore, we used 2 μM Tat-Hsp27 in 
subsequent experiments. We also performed immunocytochemistry 
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using an anti-p-tau antibody conjugated to FITC (Fig. 4). SH-SY5Y 
cells were treated with 2 μM Tat-Hsp27 for 2 h and were subsequently 
treated with 10 nM okadaic acid for 14 h. The level of p-tau was 
significantly decreased compared with treatment with okadaic acid 
alone (n = 3). 
 A cytotoxicity assay was performed to determine whether Tat-Hsp27 
directly affected the cell death induced by hyperphosphorylated tau. We 
first evaluated the relative cell viability (RCV) in the presence of Tat-
Hsp27 alone. As shown in Figure 5A, treatment with Tat-Hsp27 alone 
did not alter the RCV of normal cells. In contrast, SH-SY5Y cells 
treated with 500 nM okadaic acid for 4 h exhibited a decrease in the 
RCV of approximately 65% (Fig. 5B). When cells were treated with 0.5 
μM or 2 μM Tat-Hsp27 followed by treatment with 500 nM okadaic 
acid, the RCV increased to approximately 96% and 92%, respectively. 
Although treatment with a higher concentration of Tat-Hsp27 appeared 
to demonstrate a slightly negative effect on the cell death induced by 
hyperphosphorylated tau, Tat-Hsp27 clearly demonstrated a protective 
effect against this cell death. 
 Treatment with 10 nM okadaic acid alone for 14 h greatly increased 
the number of TUNEL-positive cells, whereas the cells pretreated with 
2 μM Tat-Hsp27 exhibited decreased TUNEL positivity (Fig. 6A, 6B). 
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In the control group, apoptotic cells comprised 2.29% of the total 
number of cells. Following exposure to 10 nM okadaic acid, the 
percentage of apoptotic cells increased to 17.84%. However, this 
increase was inhibited by Tat-Hsp27 (4.56%). Therefore, intracellular 





In this study, the recombinant Tat-Hsp27 reduced the level of 
hyperphosphorylated tau induced by okadaic acid in SH-SY5Y 
neuroblastoma cells and prevented the apoptosis induced by abnormal 
tau aggregates in our cellular model of AD. The effect of Hsp27 on 
phosphorylated tau has recently received increasing attention. However, 
few studies have examined the therapeutic effect of Hsp27 on 
hyperphosphorylated tau, which has been implicated in the 
pathogenesis of AD. In this study, we demonstrate that Hsp27 exhibits a 
protective effect on apoptotic cell death caused by pathological tau. 
This finding suggests that Hsp27 may represent a potential protein 
therapeutic for AD.  
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Tau stabilizes microtubules; however, tau mutations that result in its 
hyperphosphorylation lead to the formation of tau filaments that can 
form twisted ribbons or rope-like filaments [2]. Tau is primarily 
phosphorylated and dephosphorylates at least thirty serine or threonine 
sites [13]. Because the phosphorylation of tau is regulated by various 
kinases, such as proline-directed protein kinases and glycogen synthase 
kinase 3, and phosphatases, such as Ser/Thr protein phosphatases 1, 2A, 
2B (calcineurin) and 2C, we used okadaic acid, which is a protein 
phosphatase inhibitor, to trigger PHF-like hyperphosphorylation of tau 
[24]. We used the AT8 antibody to detect phosphorylated tau at Ser214 
and Thr205 [25]. Okadaic acid inhibits Ser/Thr protein phosphatases 
and can induce tau hyperphosphorylation and neurodegeneration [26]. 
In AD, second to β-amyloid, tauopathy has been found to correlate with 
cognitive decline [27]. Tauopathy is prominent in all cases of early-
onset familial AD that are by definition amyloidogenic in origin 
because of mutations in the amyloid precursor protein [28]. A recent 
study reported that hyperphosphorylation of tau leads to a 20-fold 
inhibition of tau–tubulin binding affinity. This finding supports a 
critical role for tau in the pathogenesis of NFT-induced degeneration 
because the balance between kinases and phosphatases is disturbed in 
AD, resulting in the disassociation of tau from microtubules and its 
subsequent aggregation [29]. In our previous study, we demonstrated 
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that hyperphosphorylated tau, but not the overexpression of normal tau 
alone, reduces the cell viability of the neuroblastoma cell line SH-
SY5Y [30]. Thus, in the present study, a cellular model of AD was 
induced by hyperphosphorylation of endogenous tau. 
Moreover, we utilized the PTD of the HIV Tat protein to enhance the 
delivery of Hsp27, thereby enhancing its protective effect [19, 31]. 
Conjugation with specific peptide sequences, which are termed PTDs 
or cell-penetrating peptides, improves the delivery of a range of agents, 
including antisense oligonucleotides, plasmids, microbeads and 
liposomes, which suggests that these peptide sequences may represent a 
universal in vitro and in vivo cellular delivery system [23]. We 
confirmed that a fusion protein of Hsp27 and the Tat PTD was 
delivered into normal human neuroblastoma SH-SY5Y cells and into 
SH-SY5Y cells containing hyperphosphorylated tau induced by okadaic 
acid treatment. To determine whether Tat-Hsp27 demonstrates a 
protective effect against okadaic acid-induced cell death, SH-SY5Y 
cells containing hyperphosphorylated tau were treated with the fusion 
protein. The levels of phosphorylated tau significantly decreased 
compared with cells that were not treated with Tat-Hsp27, and the 
relative cell viability was enhanced. This result suggests that Tat-Hsp27 
represents a potential protein therapeutic for the reduction of 
hyperphosphorylated tau. 
- 15 - 
 
Protein delivery systems offer several advantages, such as the ease of 
production from synthetic or natural compounds that provoke a low 
inflammatory response [32]. In comparison to other delivery systems, 
such as gene delivery that utilizes plasmid or viral vectors, our 
recombinant Tat-Hsp27 also offers several advantages. The 
straightforward purification of Tat-Hsp27 is amenable to large-scale 
production. Moreover, Tat-Hsp27 is nontoxic and stable and can be 
readily delivered into cells. 
As previously mentioned, PTDs can readily and rapidly deliver 
proteins into cells. Drugs to treat neurodegenerative diseases must be 
capable of penetrating the blood-brain barrier (BBB) to be effectively 
delivered [33]. However, greater than 98% of all potential CNS drugs 
cannot cross the BBB [34]. Hence, we designed a recombinant Tat-
Hsp27 fusion protein to treat a cellular AD model, and this fusion 
protein was delivered into cells at high levels within 2 h (Fig. 2). 
Therefore, we anticipate that uptake of Tat-Hsp27 into the brain will 
readily occur when nasally administered and will protect against the 
cell death caused by hyperphosphorylated tau, which is one of the 
primary causes of AD [34, 35]. Thus, we suggest that Tat-Hsp27 
demonstrates a protective effect against hyperphosphorylated tau and 
may represent a valuable protein therapeutic for AD.  
 




In this study, Tat protein transduction domain-heat shock protein 27 
fusion protein (Tat-Hsp27) effectively reduced hyperphosphorylate tau, 
apoptotic cell death. Moreover, this Tat-Hsp27 is nontoxic and stable 
and also can be readily effectively delivered. Therefore, Tat-Hsp27 
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Figure 1. Purification of His-tagged Tat-Hsp27. (A) pET28a vector 
containing hexahistidine and Tat protein transduction domain and 
Hsp27 cDNA. (B) His-tagged Tat-Hsp27 was eluted from the affinity 
chromatography column using isocratic elusion buffer (20 mM Tris-
HCl, pH 7.5, 500 mM NaCl, and 1 M imidazole). (C) His-tagged Tat-
Hsp27 was further purified using size exclusion chromatography (20  
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mM Tris-HCl, pH 7.5, and 100 mM NaCl) and eluted as a single peak. 
Fractions were analyzed using SDS-PAGE after each purification step. 
(D) Western blot analysis of purified His-tagged Tat-Hsp27 using anti-














- 23 - 
 
 
Figure 2. Transduction of wt-Hsp27 and Tat-Hsp27 into SH-SY5Y 
cells. (A) Immunocytochemistry. FITC-conjugated wt-Hsp27 or Tat-
Hsp27 was delivered into cells and analyzed 2 h later. Image restoration 
microscopy indicates that Tat-Hsp27 was rapidly and efficiently 
delivered, in contrast to wt-Hsp27. Scale bar: 30 μm. (B) Protein from 
cell lysates of SH-SY5Y cells treated with wt-Hsp27 or Tat-Hsp27 was 
analyzed using Western blot analysis. The protein expression was 
normalized to actin. 
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Figure 3. Effect of Tat-Hsp27 on tau hyperphosphorylation. Western 
blot analysis of normal tau and phosphorylated tau, with β-actin as a 
loading control. *p < 0.05 compared with the control. **p < 0.05 
compared with okadaic acid alone. The data are presented as the mean 
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Figure 5. Cytotoxicity assay using the Cell Counting Kit-8. SH-SY5Y 
cells were transduced with 0.5 μM or 2 μM Tat-Hsp27 alone (A) or 
prior to treatment with 0.5 µM okadaic acid (B). The transduction of 
Tat-Hsp27 alone does not affect the cell viability. *p < 0.05 compared 
with the control. **p < 0.01 compared with okadaic acid alone. The 
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8. Abstract in Korean (국문초록) 
 
알츠하이머는 뇌 기능을 점차 상실하게 되는 노화관련 
신경퇴행성 질병이다.  세포 골격 유지에 관여하는 타우 
단백질이 과인산화되면서 불용해성 섬유인 세포내 신경
원섬유엉킴 (neurofibrillary tangles, NFTs)가 형성되는데, NFTs
는 알츠하이머를 결정짓는 병리학적 증상으로 알려져 있다. 
따라서 타우 단백질의 과인산화를 조절하는 것은 알츠
하이머의 치료에 있어 중요하고 기본적인 접근법이라 할 
수 있다.  
열 충격 단백질 (Hsp)은 비정상적인 접힘을 이루는 단
백질이 정상적인 접힘을 할 수 있도록 돕는 역할을 
한다. 이와 관련하여 신경퇴행성과 열 충격 단백질과의 관
계가 최근 연구되고 있지만 아직 알츠하이머 치료제로
써의 연구는 미비한 상황이다. 본 연구에서는 Hsp27을 이
용하여 알츠하이머 유발 모델에서의 치료효과를 입증하였다. 
Hsp27을 세포 내로 효과적으로 전달하기 위하여 단백
질 전달 도메인（protein transduction domain, PTD) Tat을 열 
충격 단백질 27에 연결하였다（Tat-Hsp27). 타우 단백질의 
- 29 - 
 
과인산화를 유도한 후 Tat-Hsp27을 처리하여 과인산화된 
타우 단백질의 감소를 확인하였고 이로 인해 세포 생존률 또
한 크게 향상되는 것을 확인하였다. 
 
주요어: 타우 단백질, 과인산화, 알츠하이머 병, 열 충격 단백
질 27, 단백질 전달 도메인 
학  번: 2012-23040 
 
